MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s11748-026-02354-z

Медицинская библиотека · General thoracic and cardiovascular surgery · 2026

Real-world outcomes of unresected non-small cell lung cancer following neoadjuvant chemoimmunotherapy.

Akamine Takaki, Hayasaka Kazuki, Takada Kazuki, Nomura Kotaro, Watanabe Takuya, Takamori Shinkichi, Katsumata Shinya, Hamada Akira, Haratake Naoki, Shimokawa Mototsugu, Tsuboi Masahiro, Soh Junichi, Ohde Yasuhisa, CReGYT group

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

Although neoadjuvant chemoimmunotherapy is promising for resectable stage II-III non-small cell lung cancer (NSCLC), some patients do not proceed to surgery. We aimed to investigate the clinical course and outcomes of patients whose surgery was cancelled after neoadjuvant chemoimmunotherapy.

METHODS

This retrospective multicentre study (CReGYT-04: Neo-Venus study) included patients with resectable clinical stage II-III NSCLC who received nivolumab neoadjuvant chemotherapy (2023-2024). Clinical characteristics were compared between a surgery-cancelled group and surgery-performed group. In the surgery-cancelled group, the reasons for surgery cancellation, salvage treatments, and effects of immune-related adverse events (irAEs) were evaluated.

RESULTS

Among 126 patients, 11 (8.7%) did not undergo surgery. Compared with the surgery-performed group, the surgery-cancelled group had a heavier smoking history, a higher frequency of adjacent organ invasion, a greater proportion of squamous cell carcinoma histology, and more frequent Grade 3-4 irAEs. Reasons for cancelling surgery included disease progression (n = 6, 55%), patient refusal (n = 3, 27%), and irAEs (n = 2, 18%). Four (36%) patients received intensive salvage treatment (concurrent chemoradiotherapy, 3 patients; chemoimmunotherapy, 1 patient), whereas seven patients received best supportive care (n = 4) or less-intensive salvage treatment such as radiotherapy alone (n = 2) and docetaxel monotherapy (n = 1). Among the four patients in the surgery-cancelled group who developed Grade 3-4 irAEs, none received intensive salvage treatment.

CONCLUSIONS

Intensive salvage treatment was administered to 36% of patients whose surgery was cancelled after neoadjuvant chemoimmunotherapy. These findings highlight the importance of optimising patient selection and irAE management to preserve opportunities for curative-intent treatment when adopting neoadjuvant strategies.

Для цитирования: Akamine Takaki, Hayasaka Kazuki, Takada Kazuki, Nomura Kotaro, Watanabe Takuya, Takamori Shinkichi, Katsumata Shinya, Hamada Akira, Haratake Naoki, Shimokawa Mototsugu, Tsuboi Masahiro, Soh Junichi, Ohde Yasuhisa, CReGYT group. Real-world outcomes of unresected non-small cell lung cancer following neoadjuvant chemoimmunotherapy.. General thoracic and cardiovascular surgery. 2026. DOI: 10.1007/s11748-026-02354-z.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.